United States Biotechnology & Medical Research

Q32 Bio Inc. (QTTB)

Track

Track

Q32 Bio Inc. experienced three executive sales totaling approximately $275,144 during the last quarter. These divestments occurred following an earnings report that beat expectations. Despite this recent activity, the stock price has declined by 54.8% over the past ninety days, reflecting significant downward pressure on the company's market valuation.
Ticker: QTTB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Q32 Bio Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.1
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
145.39
Quantity 7,269 -45.4%
Value US$4,937,745
1.9
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
443.60
Quantity 86,515 +49.2%
Value US$4,341,847
2.8
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
23.85
Quantity 55,997 -31.8%
Value US$263,583
1.9
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
16.56
Quantity 2,798 -2.1%
Value US$46,335
2.1
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
16.56
Quantity 9,845 -2.8%
Value US$163,033
2.8
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
16.56
Quantity 3,972 -2.8%
Value US$65,776
Xu Diyong Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 625,000 +inf%
Value US$5,000,000
Xu Diyong Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 1,250,000 +55.5%
Value US$10,000,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 625,000 +inf%
Value US$5,000,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 1,250,000 +55.5%
Value US$10,000,000
2.8
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
4.51
Quantity 3,995 -10.0%
Value US$18,035
1.9
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
4.51
Quantity 2,815 -4.8%
Value US$12,708
2.1
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
4.51
Quantity 9,896 -10.0%
Value US$44,675
2.8
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
3.46
Quantity 9,072 -18.5%
Value US$31,395
2.1
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
3.46
Quantity 22,506 -18.5%
Value US$77,871
2.1
JODIE MORRISON Officer; Director Executive Director
Transaction date
Proposed sale
Price
3.46
Quantity 22,506
Value US$77,871
2.8
LEE KALOWSKI Officer Officer
Transaction date
Proposed sale
Price
3.46
Quantity 9,072
Value US$31,395
2.1
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
1.80
Quantity 10,494 -8.0%
Value US$18,900
2.8
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
1.80
Quantity 4,240 -8.0%
Value US$7,636
1.9
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
1.80
Quantity 2,990 -4.9%
Value US$5,385
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Sale
Price
24.20
Quantity 265 -3.2%
Value US$6,413
Michaud Charles Jr See Remarks Officer
Transaction date
Planned sale
Price
24.20
Quantity 75 -7.5%
Value US$1,815
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
24.21
Quantity 268 -9.4%
Value US$6,488
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Planned sale
Price
0.57
Quantity 13,037 -9.2%
Value US$7,445
Michaud Charles Jr See Remarks Officer
Transaction date
Planned sale
Price
0.57
Quantity 1,708 -12.8%
Value US$975
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
0.57
Quantity 7,280 -20.6%
Value US$4,120
Seymour Albert See Remarks Executive Director
Transaction date
Planned sale
Price
1.15
Quantity 1,448 -1.0%
Value US$1,665
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Sale
Price
1.39
Quantity 1,308 -14.9%
Value US$1,818
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 109 -2.6%
Value US$152
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 436 -10.1%
Value US$606
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.31
Quantity 99 -3.5%
Value US$130
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
1.45
Quantity 10,965 -39.6%
Value US$15,863
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Planned sale
Price
1.39
Quantity 10,616 -8.9%
Value US$14,762
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
1.39
Quantity 3,090 -13.3%
Value US$4,296
Blum Michael Lee Chief Commercial Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 2,454 -15.3%
Value US$3,412
Smith W Bradford See Remarks Officer
Transaction date
Planned sale
Price
1.39
Quantity 3,729 -20.8%
Value US$5,188
Seymour Albert See Remarks Executive Director
Transaction date
Planned sale
Price
1.39
Quantity 3,620 -2.5%
Value US$5,033
Cohn Gabriel Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,661 -38.7%
Value US$6,279
Smith W Bradford CFO & Treasurer Officer
Transaction date
Planned sale
Price
3.78
Quantity 2,182 -33.1%
Value US$8,248
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,661 -1.2%
Value US$6,279
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
3.78
Quantity 5,354 -5.9%
Value US$20,239
2.9
Kelly Timothy P Chief Operating Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,406 -38.7%
Value US$5,315
Smith W Bradford CFO & Treasurer Officer
Transaction date
Planned sale
Price
14.25
Quantity 13,500 -100.0%
Value US$192,425
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.00
Quantity 500 -100.0%
Value US$6,500
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
12.37
Quantity 4,000 -100.0%
Value US$49,460
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.00
Quantity 500 -100.0%
Value US$6,500
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.05
Quantity 5,103 -3.8%
Value US$61,469
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.06
Quantity 9,897 -6.9%
Value US$119,395
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
11.44
Quantity 10,000 -6.5%
Value US$114,422
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
11.50
Quantity 4,000 -100.0%
Value US$45,983
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
12.82
Quantity 20,000 -9.9%
Value US$256,400
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
12.82
Quantity 20,000 -9.9%
Value US$256,400
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
12.82
Quantity 480,000 -9.9%
Value US$6,153,600
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
12.82
Quantity 480,000 -9.9%
Value US$6,153,600
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
11.88
Quantity 13,703 -6.4%
Value US$162,792
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
13.06
Quantity 6,297 -2.8%
Value US$82,244
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
11.88
Quantity 328,862 -6.4%
Value US$3,906,881
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
11.88
Quantity 13,703 -6.4%
Value US$162,792
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
13.06
Quantity 6,297 -2.8%
Value US$82,244
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
11.88
Quantity 328,862 -6.4%
Value US$3,906,881
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
13.06
Quantity 151,138 -2.8%
Value US$1,973,998
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
13.06
Quantity 151,138 -2.8%
Value US$1,973,998
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.01
Quantity 1,315 -100.0%
Value US$17,109
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
16.16
Quantity 12,500 -13.9%
Value US$202,021
Smith W Bradford CFO, Treasurer & Secretary
Transaction date
Planned sale
Price
16.16
Quantity 12,000 -100.0%
Value US$193,866
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.45
Quantity 509,970 -100.0%
Value US$7,879,036
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.45
Quantity 8,857 -1.7%
Value US$136,808
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.51
Quantity 65,891 -11.3%
Value US$1,021,936
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.77
Quantity 193,359 -24.9%
Value US$3,049,600
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.69
Quantity 380,256 -32.8%
Value US$5,965,000
Smith W Bradford CFO, Treasurer & Secretary
Transaction date
Planned sale
Price
20.50
Quantity 6,000 -100.0%
Value US$122,984
Seymour Albert Chief Scientific Officer
Transaction date
Planned sale
Price
20.50
Quantity 9,133 -5.6%
Value US$187,216
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
20.50
Quantity 12,500 -12.2%
Value US$256,191
Flynn James E Large shareholder
Transaction date
Sale
Price
21.95
Quantity 151,233 -7.9%
Value US$3,319,579
Flynn James E Large shareholder
Transaction date
Sale
Price
21.95
Quantity 198,767 -7.9%
Value US$4,362,956
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-14 2026-10-06 S Sale
2.1
Morrison Jodie Pope

CEO

Executive Director
7,269 -45.4%
145.39
US$4,937,745 		7,269 -45.4% 145.39 US$4,937,745
2026-10-14 2026-10-06 S Sale
1.9
Violette Shelia M.

Chief Scientific Officer

Officer
86,515 +49.2%
443.60
US$4,341,847 		86,515 +49.2% 443.60 US$4,341,847
2026-10-14 2026-10-06 S Sale
2.8
Kalowski Lee

CFO and President

Officer
55,997 -31.8%
23.85
US$263,583 		55,997 -31.8% 23.85 US$263,583
2026-08-27 2026-08-25 S Sale
1.9
Violette Shelia M.

Chief Scientific Officer

Officer
2,798 -2.1%
16.56
US$46,335 		2,798 -2.1% 16.56 US$46,335
2026-08-27 2026-08-25 S Sale
2.1
Morrison Jodie Pope

CEO

Executive Director
9,845 -2.8%
16.56
US$163,033 		9,845 -2.8% 16.56 US$163,033
2026-08-27 2026-08-25 S Sale
2.8
Kalowski Lee

CFO and President

Officer
3,972 -2.8%
16.56
US$65,776 		3,972 -2.8% 16.56 US$65,776
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
625,000 +inf%
8.00
US$5,000,000 		625,000 +inf% 8.00 US$5,000,000
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
1,250,000 +55.5%
8.00
US$10,000,000 		1,250,000 +55.5% 8.00 US$10,000,000
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
625,000 +inf%
8.00
US$5,000,000 		625,000 +inf% 8.00 US$5,000,000
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,250,000 +55.5%
8.00
US$10,000,000 		1,250,000 +55.5% 8.00 US$10,000,000
2026-02-27 2026-02-25 S Sale
2.8
Kalowski Lee

CFO and President

Officer
3,995 -10.0%
4.51
US$18,035 		3,995 -10.0% 4.51 US$18,035
2026-02-27 2026-02-25 S Sale
1.9
Violette Shelia M.

Chief Scientific Officer

Officer
2,815 -4.8%
4.51
US$12,708 		2,815 -4.8% 4.51 US$12,708
2026-02-27 2026-02-25 S Sale
2.1
Morrison Jodie Pope

CEO

Executive Director
9,896 -10.0%
4.51
US$44,675 		9,896 -10.0% 4.51 US$44,675
2025-12-04 2025-12-02 S Sale
2.8
Kalowski Lee

CFO and President

Officer
9,072 -18.5%
3.46
US$31,395 		9,072 -18.5% 3.46 US$31,395
2025-12-04 2025-12-02 S Sale
2.1
Morrison Jodie Pope

CEO

Executive Director
22,506 -18.5%
3.46
US$77,871 		22,506 -18.5% 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
2.1
JODIE MORRISON

Officer; Director

Executive Director
22,506
3.46
US$77,871 		22,506 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
2.8
LEE KALOWSKI

Officer

Officer
9,072
3.46
US$31,395 		9,072 3.46 US$31,395
2025-08-28 2025-08-26 S Sale
2.1
Morrison Jodie Pope

CEO

Executive Director
10,494 -8.0%
1.80
US$18,900 		10,494 -8.0% 1.80 US$18,900
2025-08-28 2025-08-26 S Sale
2.8
Kalowski Lee

CFO and President

Officer
4,240 -8.0%
1.80
US$7,636 		4,240 -8.0% 1.80 US$7,636
2025-08-28 2025-08-26 S Sale
1.9
Violette Shelia M.

Chief Scientific Officer

Officer
2,990 -4.9%
1.80
US$5,385 		2,990 -4.9% 1.80 US$5,385
2024-08-14 2024-03-25 S Sale
TZIANABOS ARTHUR
Non-Executive Director
265 -3.2%
24.20
US$6,413 		265 -3.2% 24.20 US$6,413
2024-04-23 2024-03-25 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
75 -7.5%
24.20
US$1,815 		75 -7.5% 24.20 US$1,815
2024-04-23 2024-03-25 PlS Planned sale
Alloway Paul

See Remarks

Officer
268 -9.4%
24.21
US$6,488 		268 -9.4% 24.21 US$6,488
2024-02-15 2024-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
13,037 -9.2%
0.57
US$7,445 		13,037 -9.2% 0.57 US$7,445
2024-01-05 2024-01-03 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
1,708 -12.8%
0.57
US$975 		1,708 -12.8% 0.57 US$975
2024-01-05 2024-01-03 PlS Planned sale
Alloway Paul

See Remarks

Officer
7,280 -20.6%
0.57
US$4,120 		7,280 -20.6% 0.57 US$4,120
2023-09-08 2023-09-06 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
1,448 -1.0%
1.15
US$1,665 		1,448 -1.0% 1.15 US$1,665
2023-08-07 2023-08-03 S Sale
1.4
Jordan Julie

Chief Medical Officer

Officer
1,308 -14.9%
1.39
US$1,818 		1,308 -14.9% 1.39 US$1,818
2023-08-07 2023-08-03 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
109 -2.6%
1.39
US$152 		109 -2.6% 1.39 US$152
2023-08-07 2023-08-03 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
436 -10.1%
1.39
US$606 		436 -10.1% 1.39 US$606
2023-08-04 2023-08-02 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
99 -3.5%
1.31
US$130 		99 -3.5% 1.31 US$130
2023-03-06 2023-03-02 PlS Planned sale
Alloway Paul

See Remarks

Officer
10,965 -39.6%
1.45
US$15,863 		10,965 -39.6% 1.45 US$15,863
2023-01-11 2023-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
10,616 -8.9%
1.39
US$14,762 		10,616 -8.9% 1.39 US$14,762
2023-01-11 2023-01-09 PlS Planned sale
Alloway Paul

See Remarks

Officer
3,090 -13.3%
1.39
US$4,296 		3,090 -13.3% 1.39 US$4,296
2023-01-11 2023-01-09 PlS Planned sale
Blum Michael Lee

Chief Commercial Officer

Officer
2,454 -15.3%
1.39
US$3,412 		2,454 -15.3% 1.39 US$3,412
2023-01-11 2023-01-09 PlS Planned sale
Smith W Bradford

See Remarks

Officer
3,729 -20.8%
1.39
US$5,188 		3,729 -20.8% 1.39 US$5,188
2023-01-11 2023-01-09 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
3,620 -2.5%
1.39
US$5,033 		3,620 -2.5% 1.39 US$5,033
2022-01-12 2022-01-05 PlS Planned sale
Cohn Gabriel

Chief Medical Officer

Officer
1,661 -38.7%
3.78
US$6,279 		1,661 -38.7% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
2,182 -33.1%
3.78
US$8,248 		2,182 -33.1% 3.78 US$8,248
2022-01-12 2022-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
1,661 -1.2%
3.78
US$6,279 		1,661 -1.2% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
5,354 -5.9%
3.78
US$20,239 		5,354 -5.9% 3.78 US$20,239
2022-01-12 2022-01-05 PlS Planned sale
2.9
Kelly Timothy P

Chief Operating Officer

Officer
1,406 -38.7%
3.78
US$5,315 		1,406 -38.7% 3.78 US$5,315
2021-02-09 2021-02-08 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
13,500 -100.0%
14.25
US$192,425 		13,500 -100.0% 14.25 US$192,425
2021-02-05 2021-02-02 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-02-03 2021-02-01 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
12.37
US$49,460 		4,000 -100.0% 12.37 US$49,460
2021-01-14 2021-01-12 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-01-08 2021-01-07 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
5,103 -3.8%
12.05
US$61,469 		5,103 -3.8% 12.05 US$61,469
2021-01-08 2021-01-06 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
9,897 -6.9%
12.06
US$119,395 		9,897 -6.9% 12.06 US$119,395
2021-01-07 2021-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
10,000 -6.5%
11.44
US$114,422 		10,000 -6.5% 11.44 US$114,422
2021-01-06 2021-01-04 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
11.50
US$45,983 		4,000 -100.0% 11.50 US$45,983
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-03-18 2020-03-17 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
1,315 -100.0%
13.01
US$17,109 		1,315 -100.0% 13.01 US$17,109
2020-02-05 2020-02-03 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -13.9%
16.16
US$202,021 		12,500 -13.9% 16.16 US$202,021
2020-02-05 2020-02-03 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
12,000 -100.0%
16.16
US$193,866 		12,000 -100.0% 16.16 US$193,866
2020-01-31 2020-01-30 S Sale
2.8
Flynn James E
Large shareholder
509,970 -100.0%
15.45
US$7,879,036 		509,970 -100.0% 15.45 US$7,879,036
2020-01-31 2020-01-29 S Sale
2.8
Flynn James E
Large shareholder
8,857 -1.7%
15.45
US$136,808 		8,857 -1.7% 15.45 US$136,808
2020-01-28 2020-01-28 S Sale
2.8
Flynn James E
Large shareholder
65,891 -11.3%
15.51
US$1,021,936 		65,891 -11.3% 15.51 US$1,021,936
2020-01-28 2020-01-27 S Sale
2.8
Flynn James E
Large shareholder
193,359 -24.9%
15.77
US$3,049,600 		193,359 -24.9% 15.77 US$3,049,600
2020-01-28 2020-01-24 S Sale
2.8
Flynn James E
Large shareholder
380,256 -32.8%
15.69
US$5,965,000 		380,256 -32.8% 15.69 US$5,965,000
2020-01-03 2020-01-02 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
6,000 -100.0%
20.50
US$122,984 		6,000 -100.0% 20.50 US$122,984
2020-01-03 2020-01-02 PlS Planned sale
Seymour Albert

Chief Scientific Officer
9,133 -5.6%
20.50
US$187,216 		9,133 -5.6% 20.50 US$187,216
2020-01-03 2020-01-02 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -12.2%
20.50
US$256,191 		12,500 -12.2% 20.50 US$256,191
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
151,233 -7.9%
21.95
US$3,319,579 		151,233 -7.9% 21.95 US$3,319,579
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
198,767 -7.9%
21.95
US$4,362,956 		198,767 -7.9% 21.95 US$4,362,956
Explore more

More insider trading research around Q32 Bio Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America